AKERO THERAPEUTICS INC. - COMMON STOCK

28.25

27-December-24 15:45:00

15 minutes delayed

Stocks

-0.64

-2.22%

Today's range

27.51 - 28.99

ISIN

N/A

Source

NASDAQ

Akero Therapeutics Appoints Yuan Xu to its Board of Directors

26 Apr 2021 07:00:01 By Nasdaq GlobeNewswire
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)

23 Mar 2021 07:00:01 By Nasdaq GlobeNewswire
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C

22 Mar 2021 15:01:00 By Nasdaq GlobeNewswire
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

22 Mar 2021 05:30:00 By Nasdaq GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

16 Mar 2021 07:00:03 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
5
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.